ImpediMed Announces End Stage Renal Disease Trial Agreement
Filed with ASX · · 3 pages · English
Watch ImpediMed's latest callImpediMed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of ImpediMed (ASX:IPD) Q1 2027 Earnings Call+ RESEARCH SMO (“Balboa”) and Frenova Renal Research, a Fresenius Medical Care Company, to conduct an initial Observational Trial. The Company is also very pleased to announce that Dr Mark Boiskin and Dr Dylan Steer have agreed to serve as Principal Investigators for both the Observational Trial and a pivotal Interventional Trial, which will be used to support an FDA clearance for renal failure. T
Earlier from ImpediMed
- PREVENT Trial Peer-Reviewed and Published
- Share Purchase Plan Successfully Completed
- AGM Presentation - November 2021
- 2021 Annual General Meeting - Chairmans Address
- AstraZeneca extends and increases HF & Renal Contract
Later from ImpediMed
- S&P DJI Announces March 2022 Quarterly Rebalance
- AstraZeneca extends and increases Renal Contract
- Appendix 4C & Quarterly Activities Report
- Lymphoedema Risk Factors Paper Published
- ImpediMed CEO Announces Departure
Follow ImpediMed into a list and get an email when it puts out news.
Follow ImpediMed